DigiTx Partners

We focus on investment opportunities within the healthcare and life science markets where we can identify value early. At the core of our investment philosophy is a committed and collaborative approach to working with management teams and syndicate partners to build successful companies. We work actively with founders, providing guidance, support and access to our network. We strongly believe that no two investments are the same and support the most suitable business model for each individual venture, working with management teams to formulate strategies to achieve financial independence. We are comfortable financing companies by ourselves and, if appropriate, working closely with the founders to help build a syndicate of co-investors who bring complementary relationships and share our vision. We have a 14-year history of continuous dedication to the fast growing MedTech sector and a history of backing successful entrepreneurs transforming healthcare through MedTech innovation. Investment Strategy Focus: Within the broader healthcare market, we focus our investments on medical technologies including medical devices, diagnostics, drug delivery, and digital health. We back both first-time and experienced founders, who value our participation as well our capital. Stage: We are typically the first institutional investor and support companies through early product and clinical development and often through the regulatory process. We make our first investment at the seed through series B stage, based on when the risk of translation from pre-clinical to clinical is at its lowest. We are life cycle investors and continue to support our portfolio companies through to exit. Capital Efficiency: We invest in companies that are able to demonstrate early and meaningful clinical value with minimum capital invested and preserve the most appropriate exit opportunity. Therapeutic Indications: While we are agnostic to therapeutic indication, we invest in companies developing products that address large, global markets and where there is significant unmet clinical need. We particularly like therapeutic devices that significantly improve patient outcomes and diagnostics that fundamentally change the course of therapeutic intervention.

AGP is a fund management company spun out from EDBI, a state-owned fund in Singapore, with former senior employees as founders. The fund will continue to have close affiliation to EDBI providing unique opportunities for collaboration and investments. We are raising a dedicated healthcare fund (“AGP Healthcare Fund” or “AGPHC”) to build on our successes at EDBI and to capture new opportunities. Our partners have a credible reputation built on years of working together at EDBI and having strong domain expertise in healthcare, with extensive network and deep linkages to the Singapore, regional, and global biomedical and healthcare ecosystem. Our investment areas* include medtech & manufacturing, services & others, healthtech, and biotech & therapeutics. At AGP Healthcare Fund, we focus on investing in growth-stage companies (Series C to pre-IPO) (~75%) and venture-stage companies (Series A and B) (~25%). Our unique position in serving both SEA/Asia and global markets is driven by our belief that SEA is an emerging innovation hub with tremendous potential to build differentiated and valuable healthcare companies. We see opportunities for healthcare companies to capitalize on the Asian growth momentum by leveraging Singapore's position as a nexus between the East and the West. With our global insights and proven track record, we provide valuable guidance and advice to founders in expanding their businesses globally. Investment areasMedtech & Mfg, Services & Others: minimally invasive devices, medical equipment manufacturing & distribution, surgical robotics, diagnostics, healthcare services, new modalities CRDMOs, life science equipment & consumables, drug manufacturing & distribution Healthtech: remote patient monitoring, virtual care delivery, digital health platform, workflow automation, healthcare analytics, AI in healthcare imaging, digital therapeutics, chronic disease management Biotech & Therapeutics: cell & gene therapy, RNA therapeutics, AI drug discovery, targeted therapy & immunotherapy, gene editing tools & infrastructure, regenerative medicine & tissue engineering, and life science tools

DaVita Venture Group is committed to building partnerships with health care innovators to help improve the lives of patients with kidney disease and related conditions. Together, we believe we can transform the future of patient care for the better. Our Strategy We aim to invest in, acquire, and co-develop products, solutions and businesses that improve care for patients with kidney disease and related conditions. PrioritiesCare Delivery Models: Advancements to expand access to care and improve clinical outcomes through adoption of tech-enabled services, home treatments and value-based care Life Sciences: Pharmaceuticals, medical devices and diagnostics that can improve clinical outcomes and patient experience while reducing costs Digital Health: Products and services that leverage technology, data and connectivity to improve care delivery

Our strategy leverages an extensive hospital system and health plan network of relationships to target attractive market segments, to identify and evaluate investment opportunities, and to support the growth of our portfolio companies. Current Areas of Focus:Administrative Automation Behavioral Health: HCIT & Services Data Security Digital Therapeutics Genomics: Applications & Analytics Patient Safety & Risk Monitoring Pharma Data & Analytics Platforms Social Determinants of Health Virtual Care Models Women’s Health: HCIT & Services

Our focus is on opportunities that are beyond proof of concept and poised for more significant development and growth in the Medical Device, Life Science Tool, Diagnostic and Digital Health sectors. Why Gilmartin Capital? The investing landscape is long on capital and short on insight. Our value extends beyond capital. We possess extensive domain expertise in areas such as strategy, market assessment, and capital markets advisory. Our passion is to avail our experience and network to help you solve problems, drive scientific discovery, help patients and grow. For over two decades, we have amassed a propriety expert network consisting of key opinion leaders across multiple therapeutic verticals and technical specialties, and best-in-class operators in various operational, scientific, and financial areas. In fact, the majority of our fund capital comes from operators like you. The founding partners have decades of experience analyzing and advising healthcare technology companies. We do the math! We want to help you advance your vision.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.